He et al.recently reported in Nature Communications1 the development of a protein vaccine against SASR-CoV-2 Omicron variant consisting of a trimer of the spike protein receptor-binding domain(RBD)of the Delta variant...He et al.recently reported in Nature Communications1 the development of a protein vaccine against SASR-CoV-2 Omicron variant consisting of a trimer of the spike protein receptor-binding domain(RBD)of the Delta variant fused to heptad-repeat sequences 1 and 2.This vaccine induced broad-spectrum neutralizing antibodies and fully protected mice and non-human primates against challenge with live Delta and Omicron virus.展开更多
基金supported by Instituto de Salud Carlos III,Fondo Europeo de Desarrollo Regional"Una manera de hacer Europa"under grant PI20/00260,Gobierno de Navarra under grant 0011-3597-2020-000024 to PS and by Paula&Rodger Riney Foundation to JJL.
文摘He et al.recently reported in Nature Communications1 the development of a protein vaccine against SASR-CoV-2 Omicron variant consisting of a trimer of the spike protein receptor-binding domain(RBD)of the Delta variant fused to heptad-repeat sequences 1 and 2.This vaccine induced broad-spectrum neutralizing antibodies and fully protected mice and non-human primates against challenge with live Delta and Omicron virus.
